Provided by Tiger Trade Technology Pte. Ltd.

ImmunityBio, Inc.

8.56
+0.35004.26%
Pre-market: 8.48-0.0800-0.93%05:29 EDT
Volume:22.46M
Turnover:192.32M
Market Cap:8.80B
PE:-22.41
High:8.92
Open:8.08
Low:8.05
Close:8.21
52wk High:12.43
52wk Low:1.83
Shares:1.03B
Float Shares:336.00M
Volume Ratio:1.04
T/O Rate:6.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3820
EPS(LYR):-0.3820
ROE:78.05%
ROA:-36.17%
PB:-17.58
PE(LYR):-22.41

Loading ...

ImmunityBio Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Feb 24

ImmunityBio Founder Patrick Soon-Shiong to Speak at Milken Institute and Richard Nixon Foundation Cancer 2035 Summit

Reuters
·
Feb 24

ImmunityBio price target raised to $15 from $10 at H.C. Wainwright

TIPRANKS
·
Feb 24

ImmunityBio Explodes To Near 52-Week High As Bladder Cancer Drug Anktiva Drives Massive 700% Revenue Growth

Benzinga
·
Feb 24

ImmunityBio rises 25.2%

TIPRANKS
·
Feb 23

BUZZ-ImmunityBio rises as cancer drug therapy sales surge, global approvals expand

Reuters
·
Feb 23

ImmunityBio Q4 EPS $(0.06) Beats $(0.09) Estimate, Sales $38.285M Beat $37.020M Estimate

Benzinga
·
Feb 23

Earnings Flash (IBRX) ImmunityBio Posts Q4 Net Loss $0.06 a Share, vs. FactSet Est of $0.09 Loss

MT Newswires Live
·
Feb 23

ImmunityBio FY 2025 net product revenue hits USD 113M on ~700% growth

Reuters
·
Feb 23

Immunitybio Reports 700% Year-Over-Year Revenue Growth, Expanded Anktiva® Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries With Label Expansion Plans Globally

THOMSON REUTERS
·
Feb 23

Immunitybio Inc: Qtrly EPS $ -0.06

THOMSON REUTERS
·
Feb 23

Immunitybio Inc: Qtrly Total Revenue $38.3 Mln

THOMSON REUTERS
·
Feb 23

Mixed options sentiment in ImmunityBio with shares down 0.99%

TIPRANKS
·
Feb 21

ImmunityBio Partners With Biopharma and Cigalah to Launch ANKTIVA in Saudi Arabia

Reuters
·
Feb 20

Immunitybio Partners With Biopharma and Cigalah Healthcare to Launch Anktiva® in Saudi Arabia for Bladder and Lung Cancer Patients

THOMSON REUTERS
·
Feb 20

Immunitybio Inc - Anktiva Available for Distribution Within 60 Days

THOMSON REUTERS
·
Feb 20

ImmunityBio Holds Golden Cross As Stock Trades 170% Above 200-Day Average

Benzinga_recent_news
·
Feb 20

ImmunityBio partners with Accord Healthcare to provide Anktiva access

TIPRANKS
·
Feb 19

Immunitybio Expands Access to Anktiva® in EU With New Distribution Partnership and Opens Irish Subsidiary to Support European Launch

THOMSON REUTERS
·
Feb 19

ImmunityBio signs EU ANKTIVA distribution partnership with Accord Healthcare

Reuters
·
Feb 19